Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy of mycobactovir (Myc-102) in patients with acute exacerbation of chronic vulvovaginal candidiasis: A multicenter, randomised, double-blind phase III study

Trial Profile

Efficacy of mycobactovir (Myc-102) in patients with acute exacerbation of chronic vulvovaginal candidiasis: A multicenter, randomised, double-blind phase III study

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Jul 2018

At a glance

  • Drugs Myc 102 (Primary)
  • Indications Vulvovaginal candidiasis
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Jul 2018 New trial record
    • 11 Jun 2018 Primary endpoint of mycological response rate at 7 day has been met, according to results presented the ASM microbe 2018.
    • 11 Jun 2018 Results presented at the ASM Microbe 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top